Full text
Earnings transcript
Read the complete earnings call transcript.
MEDP
Medpace Holdings, Inc.
$616.22
-2.83
(-0.46%)
| Exchange: | NASDAQ |
| Market Cap: | 17.2B |
| Shares Outstanding: | 38.346M |
Delayed data
About The Company
| Sector: | Healthcare | |||||
| Industry: | Medical – Diagnostics & Research | |||||
| CEO: | August James Troendle | |||||
| Full Time Employees: | 6500 | |||||
| Address: |
| |||||
| Website: | https://www.medpace.com |
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace’s services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 1,885,842 | 2,109,054 | 2,530,234 |
| Gross Profit | 524,505 | 656,305 | 760,618 |
| EBITDA | 362,498 | 505,173 | 570,501 |
| Operating Income | 336,825 | 446,870 | 534,935 |
| Net Income | 282,810 | 404,386 | 451,123 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 1,656,828 | 2,100,866 | 1,975,472 |
| Total Liabilities | 1,097,878 | 1,275,321 | 1,516,401 |
| Total Stockholders Equity | 558,950 | 825,545 | 459,071 |
| Total Debt | 142,122 | 126,234 | 113,643 |
| Cash and Cash Equivalents | 245,449 | 669,436 | 497,049 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 433,374 | 608,815 | 713,223 |
| Capital Expenditure | -36,648 | -36,548 | 0 |
| Free Cash Flow | 396,726 | 572,267 | 713,223 |
| Net Income | 282,810 | 404,386 | 451,123 |
| Net Change in Cash | 217,184 | 423,987 | -172,387 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Research Access | Research Access | Research Access | Research Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 3,690,583.799 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (High) | 3,939,358.090 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (Avg) | 3,793,300 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Low) | 989,539.066 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (High) | 1,056,241.760 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Avg) | 1,017,079.883 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Low) | 750,933.051 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (High) | 817,291.443 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Avg) | 778,331.746 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Low) | 320,328.692 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (High) | 341,921.358 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Avg) | 329,244.069 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Avg) | 26.360 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (High) | 27.680 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Low) | 25.430 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated Revenue) | 4 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated EPS) | 3 | Research Access | Research Access | Research Access | Research Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Robust Financial Performance: MEDP demonstrates strong revenue growth and consistent net income as per the latest income statements. Positive trends in operating cash flow and free cash flow indicate operational efficiency and financial health, supporting sustained growth initiatives.
- Favorable Valuation Metrics: The current price-to-earnings (P/E) ratio TTM and forward P/E ratios suggest that MEDP is reasonably valued compared to industry averages, as indicated by the industry_avg_priceToEarningsRatioTTM. This positions the stock as an attractive investment within the sector.
- Strong Balance Sheet: High cash and cash equivalents, coupled with a manageable debt-to-equity ratio TTM, provide MEDP with financial flexibility to weather economic downturns or invest in strategic opportunities, as evidenced by balance sheet data.
- Sector and Industry Positioning: MEDP benefits from operating in a growing sector and industry, with performance metrics (perf1y, perf5y) showing outperformance relative to industry_perf1y and sector_perf1y, highlighting competitive strength.
Log in with Research Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MARKETSnap estimates MEDP intrinsic value between $263.03 – $345.64 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about MEDP valuation
Is Medpace Holdings, Inc. (MEDP) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Medpace Holdings, Inc. (MEDP) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is MEDP a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether MEDP trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is MEDP’s P/E ratio?
You can see MEDP’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for MEDP?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is MEDP a good long-term investment?
Whether MEDP fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
MEDP
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
-0.46
Trading Metrics:
| Open: | 611.08 | Previous Close: | 619.05 | |
| Day Low: | 611.08 | Day High: | 624.33 | |
| Year Low: | 373 | Year High: | 677.9 | |
| Price Avg 50: | 557.53 | Price Avg 200: | 520.71 | |
| Volume: | 63073 | Average Volume: | 357430 |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeMEDP full analysis
Welcome to MARKETSNAP’s SWOT analysis for Medpace Holdings, or MEDP as you might know it on the ticker. If you’re not familiar with Medpace, let me give you the quick rundown. This company is a key player in the clinical research space, operating within the healthcare sector, specifically in the contract research organization industry. They provide outsourced clinical development services to biotech and pharmaceutical companies, helping bring new drugs and treatments to market. Based in the U.S., Medpace has a…
